BioWorld Asia

Sep. 2, 2009

Strong Data Have Nitec Eying 2010 Filing in RA for Lodotra

Nitec Pharma AG has obtained positive data from a second Phase III trial of Lodotra in rheumatoid arthritis (RA), paving the way for a U.S. regulatory filing next year. (BioWorld International) Read More

$210M Deal Gives Endo Rights to Testosterone Gel Fortesta

Bug Contributes to Cancer: May Be 'H. Pylori of Colon Cancer'

Silence Remaining Silent on Size of Research Deal

Mondobiotech Shares on the Rise After Cashless Listing

Ark Testing Second-Generation Gene Therapy in Heart Ailment

UK Losing Leading Stem Cell Scientist: Minger Joins GE Firm

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...